• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002864.SZ
Share

Shaanxi Panlong Pharmaceutical Group Co., Ltd. Stocks

CN¥ 28.32Last Updated 10.07.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 429.56M

CN¥ 28.32
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd is a pharmaceutical enterprise based in China, comprehensively engaging in the research, development, production, and sale of pharmaceutical products. Furthermore, the company undertakes the GAP-compliant cultivation of medicinal raw materials. Its diverse product portfolio spans numerous therapeutic categories, including orthopedic, cardio-cerebrovascular, digestive, nutritional supplement, respiratory, Traditional Chinese Anti-Inflammatory, pediatric, gynecological, hepatobiliary, and various specialty drugs. Established in 1997, the company maintains its headquarters in Xi'an, China.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.07.2026 18:01

"Buffett in a Skirt": How Hetty Green Built an Empire on Crises and Saved Wall Street

12.07.2026 15:01

"The 30-Second Rule": How Investors Can Learn to Think Things Through Before Making Trades

12.07.2026 05:26

The U.S. announced a third wave of strikes against Iran following the closure of the Strait of Hormuz

11.07.2026 19:01

A Triumph for City Governments? How China’s Scaling Model Will Change the Global AI Market

11.07.2026 16:01

Highlights from Small-Caps: Royce Fund Forecast, Trump's Sons' Investments, the Chewy Case Study

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026